Journal of Antimicrobial Chemotherapy
-
Publication Venue For
-
Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditis..
72:1714-1722.
2017
-
IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting..
71:3195-3201.
2016
-
Efficacy of dual therapy with lamivudine plus darunavir boosted with ritonavir once daily in HIV-infected patients with nucleoside analogue toxicity..
70:630-632.
2015
-
Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C)..
69:471-475.
2014
-
Antimicrobial activity of copper surfaces against carbapenemase-producing contemporary Gram-negative clinical isolates..
68:852-857.
2013
-
Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli..
67:2424-2428.
2012
-
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials..
67:2020-2028.
2012
-
Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus..
66:2843-2849.
2011
-
Efficacy of carbapenems against a metallo-β-lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model..
66:611-617.
2011
-
Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster..
59:786-790.
2007
-
Multicentre surveillance of the prevalence and molecular epidemiology of macrolide resistance among pharyngeal isolates of group A streptococci in the USA..
57:1240-1243.
2006
-
Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection..
56:273-276.
2005
-
Ceftriaxone pharmacokinetics in interleukin-10-treated murine pneumococcal pneumonia..
55:721-726.
2005
-
Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials..
54:701-703.
2004
-
Emergence of fluoroquinolone resistance among Bacteroides species..
52:208-213.
2003
-
Rigorous pre-clinical evaluation of topical microbicides to prevent transmission of human immunodeficiency virus..
51:1099-1102.
2003
-
siRNAs: a new wave of RNA-based therapeutics..
51:753-756.
2003
-
A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution..
51:453-457.
2003
-
Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in human mononuclear cells identified by cDNA microarray analysis..
50:811-817.
2002
-
Effect of different classes of inhibitors on DNA gyrase from Mycobacterium smegmatis..
48:479-485.
2001
-
Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy.
46:775-784.
2000
-
Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group..
46:775-784.
2000
-
In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans..
45:231-233.
2000
-
In-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida spp..
44:223-228.
1999
-
In-vitro modelling of the bactericidal activity of teicoplanin versus flucloxacillin as used in surgical prophylaxis, against Staphylococcus aureus..
39:477-481.
1997
-
The effect of burn wound surgery and teicoplanin on the bactericidal activity of polymorphonuclear leucocytes against Staphylococcus aureus..
36:851-855.
1995
-
Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis..
33:73-81.
1994
-
Susceptibilities of anaerobic gram-negative bacilli to thirteen antimicrobials and beta-lactamase inhibitor combinations..
28:855-867.
1991
-
The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis..
26:387-397.
1990
-
The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987..
25:1011-1019.
1990
-
Differential inhibition of HIV-1 cell binding and HIV-1-induced syncytium formation by low molecular weight sulphated polysaccharides..
25:313-318.
1990
-
Enhancement of the activity of cefotaxime by iron-binding proteins..
25:479-481.
1990
-
In-vitro susceptibility of nosocomial gram-negative bloodstream pathogens to quinolones and other antibiotics--a statistical approach..
23:353-361.
1989
-
Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits..
16:81-86.
1985
-
Pharmacokinetics of N-formimidoyl thienamycin and influence of a renal dipeptidase inhibitor in experimental meningitis..
12:39-45.
1983
-
Lack of disulfiram--like reactions with ceftizoxime..
10 Suppl C:129-133.
1982
-
Comparative in-vitro activity of MK0787 (N-formimidoyl thienamycin) against 540 blood culture isolates..
9:183-194.
1982
-
Cephradine concentrations in serum, pleural fluid, pleura, and lung of normal rabbits..
8:345-346.
1981
-
Pharmacokinetics of cefoperazone, moxalactam, cefotaxime, trimethoprim and sulphamethoxazole in experimental meningitis..
8:49-58.
1981
-
Antibiotic concentrations in human parapneumonic effusions..
7:171-177.
1981
-
Penetration of cephradine into normal, inflammatory, and infected pleural fluids in rabbits..
6:143-149.
1980
-
Susceptibility of Aspergillus to 5-fluorocytosine and amphotericin B alone and in combination..
4:375-380.
1978